Company announcementCompany-reported
What was reported
EDEN PRAIRIE, Minn. – August 27, 2026 – NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today reported the successful completion of three separate large-animal procedures using its next-generation StereoCED™ platform. In two of the three procedures, NeuroOne’s drug delivery electrodes both delivered a study agent directly into targeted brain tissue and recorded intracranial electrophysiological activity from the same targeted regions.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 27, 2026 · Open the source ↗
What the evidence supports
NeuroOne Medical furnished a press release to the SEC (Form 8-K, Item 8.01) about a company announcement. It shows what the company chose to disclose on that date.
What remains unknown
Claims in the release are the company's own and have not been independently verified. Furnishing a document to the SEC does not mean the SEC reviewed or endorsed it.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineNeuroOne Announces Successful Robotic-Assisted Drug Delivery Using Next-Generation StereoCED™ PlatformU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 27, 2026 · Open the source ↗
Press release lead paragraphEDEN PRAIRIE, Minn. – August 27, 2026 – NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today reported the successful completion of three separate large-animal procedures using its next-generation StereoCED™ platform. In two of the three procedures, NeuroOne’s drug delivery electrodes both delivered a study agent directly into targeted brain tissue and recorded intracranial electrophysiological activity from the same targeted regions.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 27, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:54 UTC
NeuroOne Announces Successful Robotic-Assisted Drug Delivery Using Next-Generation StereoCED™ Platform
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.